Stockscreener 앱 받기
175.07
0.07%
-0.13
시장 영업 전:
175.07
전일 마감가:
$175.20
열려 있는:
$173.33
하루 거래량:
1.85M
Relative Volume:
0.66
시가총액:
$37.34B
수익:
$447.02M
순이익/손실:
$-1.18B
주가수익비율:
-28.32
EPS:
-6.1812
순현금흐름:
$-906.14M
1주 성능:
+0.56%
1개월 성능:
-14.18%
6개월 성능:
+79.01%
1년 성능:
+162.79%
1일 변동 폭
$170.94
$175.41
1주일 범위
$167.39
$177.90
52주 변동 폭
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - marketscreener.com
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
Market Review: Why Insmed Incorporated IM8N stock remains top ratedAnalyst Downgrade & High Conviction Investment Ideas - moha.gov.vn
Allspring Global Investments Holdings LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Calamos Advisors LLC Acquires 12,263 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insmed (FRA:IM8N) EV-to-OCF : -39.13 (As of Dec. 25, 2025) - GuruFocus
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Investors to Reach Out - ACCESS Newswire
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Insmed price target lowered to $230 from $240 at HC Wainwright - MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Pharmaceutical Stocks To ConsiderDecember 21st - MarketBeat
Why Insmed Incorporated stock is considered a top pickMarket Sentiment Extremes & Free Professional Investment Consultations - Bollywood Helpline
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insmed Inc (NASDAQ:INSM) Nasdaq Today Anchors Clinical Innovation - Kalkine Media
Insmed, Inc. (NASDAQ:INSM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open - ts2.tech
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025) - ts2.tech
Insmed Incorporated(NasdaqGS: INSM) added to NASDAQ-100 Index - marketscreener.com
How analysts rate Insmed Incorporated stock today2025 Support & Resistance & Momentum Based Trading Ideas - Улправда
What is HC Wainwright's Forecast for Insmed FY2025 Earnings? - MarketBeat
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.02%
자본화:
|
볼륨(24시간):